Nuclear receptor subfamily 4 group A member 1 (NR4A1) (NR4A1)

Nuclear receptor subfamily 4 group A member 1 (NR4A1), also known as Nur77 or TR3, is an orphan nuclear receptor that functions as an immediate-early response gene and a versatile transcription factor (NIH, 2020). It plays a critical role in maintaining cellular homeostasis by regulating diverse biological processes, including cell proliferation, apoptosis, metabolism, and immune response (NIH, 2014; Frontiers in Oncology, 2022). In solid tumors, NR4A1 often acts as a pro-oncogenic factor by coactivating growth-promoting genes in the nucleus; however, it can also function as a potent pro-apoptotic factor when it translocates to the mitochondria and interacts with Bcl-2 (NIH, 2016; PLOS One, 2014). Conversely, in hematological malignancies like acute myeloid leukemia, NR4A1 typically serves as a tumor suppressor (NIH, 2014). Therapeutic strategies targeting NR4A1 include the use of agonists to induce its pro-apoptotic mitochondrial translocation or antagonists to inhibit its nuclear transcriptional activity (NIH, 2020). Given its involvement in metabolic and inflammatory pathways, NR4A1 is also being explored as a target for treating diabetes, atherosclerosis, and autoimmune disorders (NIH, 2020).

Other names

Nur77TR3NGFI-BN10TIS1Orphan nuclear receptor NR4A1Nuclear receptor subfamily 4 group A member 1

NR4A1-targeted drugs operate through several distinct mechanisms: agonists (e.g., Cytosporone B) bind the ligand-binding domain to promote nuclear export and mitochondrial-mediated apoptosis via Bcl-2 interaction (NIH, 2020; NIH, 2014); antagonists (e.g., C-DIM compounds) inhibit nuclear NR4A1-mediated transcription of pro-survival genes like survivin and c-Myc (NIH, 2016; PLOS One, 2014); and modulators can influence NR4A1's role in metabolic regulation and T-cell exhaustion (NIH, 2022; Frontiers in Oncology, 2022).